Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

Small cell lung cancer (SCLC) is a recalcitrant cancer for which no new treatments have been approved in over 30 years. While molecular subtyping now guides treatment selection for patients with non-small cell lung cancer and other cancers, SCLC is still treated as a single disease entity. Using mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardnell, Robert J., Li, Lerong, Sen, Triparna, Bara, Rasha, Tong, Pan, Fujimoto, Junya, Ireland, Abbie S., Guthrie, Matthew R., Bheddah, Sheila, Banerjee, Upasana, Kalu, Nene N., Fan, You-Hong, Dylla, Scott J., Johnson, Faye M., Wistuba, Ignacio I., Oliver, Trudy G., Heymach, John V., Glisson, Bonnie S., Wang, Jing, Byers, Lauren A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650272/
https://www.ncbi.nlm.nih.gov/pubmed/29088717
http://dx.doi.org/10.18632/oncotarget.20621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650272/
https://www.ncbi.nlm.nih.gov/pubmed/29088717
http://dx.doi.org/10.18632/oncotarget.20621

Ejemplares similares